Brian L. VanderBeek

Brian L. VanderBeek

Auto-generated profile, based on publicly available information

Brian L. VanderBeek

University of Pennsylvania Perelman School of Medicine

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2017 in Diabetes Care
Verified
Journal Article
Open access
PDF file
SSSharon D. Solomon
Sharon D. Solomon
ECEmily Chew
Emily Chew
EDElia J. Duh
Elia J. Duh
LSLucia Sobrin
Lucia Sobrin
JSJennifer K. Sun
Jennifer K. Sun
TGThomas Gardner
Thomas Gardner
Diabetic retinopathy diagnostic assessment and treatment options have improved dramatically since the 2002 American Diabetes Association Position Statement (1). These improvements include the widespread adoption of optical coherence tomography to assess retinal thickness and intraretinal pathology and wide-field fundus photography to reveal clinically silent microvascular lesions. Treatment of diabetic macular edema is now achieved by intravitreous injection of anti–vascular endothelial growth factor agents, and the same drugs are now used for proliferative diabetic retinopathy. Improvements in medications and devices for the systemic therapy of diabetes have also improved the ability of patients to optimize their metabolic control. This Position Statement incorporates these recent developments for the use of physicians and patients. Diabetic retinopathy is a highly specific neurovascular complication of both type 1 and type 2 diabetes, the prevalence of which strongly correlates to both the duration of diabetes and level of glycemic control. A pooled meta-analysis involving 35 studies conducted worldwide from 1980 to 2008 estimated global prevalence of any diabetic retinopathy and proliferative diabetic retinopathy (PDR) among patients to be 35.4% and 7.5%, respectively (2). Diabetic retinopathy is the most frequent cause of new cases of blindness among adults aged 20–74 years in developed countries. Glaucoma, cataracts, and other disorders of the eye occur earlier and more frequently in people with diabetes. In addition to diabetes duration, factors that increase the risk of or are associated with retinopathy include chronic hyperglycemia (3,4), nephropathy (5), hypertension (6), and dyslipidemia (7). Intensive diabetes management with the goal of achieving near-normoglycemia has been shown in large prospective randomized studies to prevent and/or delay the onset and progression of diabetic retinopathy (8,9). Lowering blood pressure has been shown to decrease retinopathy progression in people with type 2 diabetes, although tight targets (systolic blood pressure <120 mmHg) do …

1 January 2012 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
BVBrian L. VanderBeek
Brian L. VanderBeek
MJMark W. Johnson
Mark W. Johnson

1 November 2015 in Ophthalmology
Verified
Journal Article
Closed access
BVBrian L. VanderBeek
Brian L. VanderBeek
SBSarah G. Bonaffini
Sarah G. Bonaffini
LMLiyuan Ma
Liyuan Ma

1 August 2011 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
BVBrian L. Vanderbeek
Brian L. Vanderbeek
DZDavid N Zacks
David N Zacks
NTNidhi Talwar
Nidhi Talwar
BNBin Nan
Bin Nan
DMDavid C. Musch
David C. Musch
JSJoshua D. Stein
Joshua D. Stein

19 August 2021 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
JSJacob Sterling
Jacob Sterling
PHPeiying Hua
Peiying Hua
JDJoshua L Dunaief
Joshua L Dunaief
QCQi N Cui
Qi N Cui
BVBrian L VanderBeek
Brian L VanderBeek
Background/aims Glucagon-like peptide-1 receptor (GLP-1R) agonists regulate blood glucose and are commonly used to treat type 2 diabetes mellitus. Recent work showed that treatment with the GLP-1R agonist NLY01 decreased retinal neuroinflammation and glial activation to rescue retinal ganglion cells in a mouse model of glaucoma. In this study, we used an insurance claims database (Clinformatics Data Mart) to examine whether GLP-1R agonist exposure impacts glaucoma risk. Methods A retrospective cohort of patients who initiated a new GLP-1R agonist was 1:3 age, gender, race, classes of active diabetes medications and year of index date matched to patients who initiated a different class of oral diabetic medication. Inverse probability of treatment weighting (IPTW) was used within a multivariable Cox proportional hazard regression model to test the association between GLP-1R agonist exposure and a new diagnosis of primary open-angle glaucoma, glaucoma suspect or low-tension glaucoma. Results Cohorts were comprised of 1961 new users of GLP-1R agonists matched to 4371 unexposed controls. After IPTW, all variables were balanced (standard mean deviation <|0.1|) between cohorts. Ten (0.51%) new diagnoses of glaucoma were present in the GLP-1R agonist cohort compared with 58 (1.33%) in the unexposed controls. After adjustment, GLP-1R exposure conferred a reduced hazard of 0.56 (95% CI: 0.36 to 0.89, p=0.01), suggesting that GLP-1R agonists decrease the risk for glaucoma. Conclusions GLP-1R agonist use was associated with a statistically significant hazard reduction for a new diagnosis of glaucoma. Our findings support further investigations into the use of GLP-1R agonists in glaucoma prevention.

1 March 2020 in JAMA Ophthalmology
Verified
Journal Article
Open access
PDF file
MRMeera S. Ramakrishnan
Meera S. Ramakrishnan
YYYinxi Yu
Yinxi Yu
BVBrian L. VanderBeek
Brian L. VanderBeek
Medication adherence has become an important metric in assessing treatment efficacy.1-4 Specific to ophthalmology, this issue has been most commonly assessed with regard to glaucoma medication adherence and persistence.5-9 While it seems self-evident that the best outcomes would naturally follow from the patients who are most adherent to the prescribing guidelines put forth by their physician, the potential association between regular physician visits and outcomes is less obvious. Visit adherence is an idea that is gaining traction across medicine but has been most extensively studied in patients with HIV. Numerous studies have shown that increased adherence with regularly scheduled visits is not only associated with reduced viral loads but also improved survival.10-13